We, and others, have shown in human ovarian cancer cell lines and xenograft mouse models that COL11A1 is not only associated with poor response to cisplatin, but also confers cisplatin resistance though multiple mechanisms. This evidence concerns the gene COL11A1 and ovarian carcinoma.